Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China Read more about Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Zai Lab Holds Virtual Research and Development Day Read more about Zai Lab Holds Virtual Research and Development Day
Zai Lab Expands U.S. Operations to Join the Cambridge Biotechnology Community Read more about Zai Lab Expands U.S. Operations to Join the Cambridge Biotechnology Community
Zai Lab Announces Breakthrough Therapy Designation Granted for Bemarituzumab (FPA144) in China Read more about Zai Lab Announces Breakthrough Therapy Designation Granted for Bemarituzumab (FPA144) in China
Zai Lab to Host Virtual Research and Development Day on September 22, 2021 Read more about Zai Lab to Host Virtual Research and Development Day on September 22, 2021
QINLOCK® (Ripretinib) Approved in Taiwan for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST) Read more about QINLOCK® (Ripretinib) Approved in Taiwan for Treatment of Advanced Gastrointestinal Stromal Tumors (GIST)
Zai Lab Announces Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in Hong Kong Read more about Zai Lab Announces Approval of ZEJULA® (Niraparib) for First-Line Maintenance Treatment of Ovarian Cancer in Hong Kong
Zai Lab Announces Upcoming Presentations in September Investor Conferences Read more about Zai Lab Announces Upcoming Presentations in September Investor Conferences
Zai Lab Announces Second Quarter 2021 Financial Results and Corporate Updates Read more about Zai Lab Announces Second Quarter 2021 Financial Results and Corporate Updates
Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology Read more about Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology